GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...

The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...

RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.

London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

U.S. sales of RSV vaccines from GSK and Pfizer (NYSE: PFE) are down significantly after regulators narrowed the targeted age ...

PHILADELPHIA, PA, USA I October 08, 2024 I GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III ...

Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

On a similar front, 3% of U.S. high school students surveyed in 2023 identified as transgender, and 25% of transgender ...

Things are, however, looking good for its latest launch, respiratory syncytial virus vaccine Arexvy, which GSK thinks can reach around $4 billion in annual sales. Zealand Pharma has suffered ...